Spondyloarthropathies: IL-6 Blockade in Psoriatic Arthritis - a New Therapeutic Option?

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2016 May 25

PMID 27215204

Citations 2

Authors

Oliver FitzGerald

Affiliations

Soon will be listed here.

Citing Articles

The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis.

Liu X, Zhao Y, Mu Z, Jia Y, Liu C, Zhang J Clin Cosmet Investig Dermatol. 2023; 16:1703-1713.

PMID: 37404370 PMC: 10315140. DOI: 10.2147/CCID.S413853.

The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.

Poubelle P, Page N, Longchamps M, Sampaio Moura N, Beck D, Aksentijevich I Clin Transl Med. 2019; 8(1):19.

PMID: 31165299 PMC: 6548783. DOI: 10.1186/s40169-019-0236-7.

References

Kane D, Stafford L, Bresnihan B, FitzGerald O . A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003; 42(12):1460-8. DOI: 10.1093/rheumatology/keg384. View

Alenius G, Eriksson C, Rantapaa Dahlqvist S . Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol. 2009; 27(1):120-3. View

Glintborg B, Ostergaard M, Krogh N, Andersen M, Tarp U, Loft A . Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013; 65(5):1213-23. DOI: 10.1002/art.37876. View

Fagerli K, Lie E, van der Heijde D, Heiberg M, Kalstad S, Rodevand E . Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013; 72(11):1840-4. DOI: 10.1136/annrheumdis-2012-203018. View

Spadaro A, Taccari E, Riccieri V, Sensi F, Sili Scavalli A, Zoppini A . Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol. 1996; 14(4):413-6. View

Haroon M, Kirby B, FitzGerald O . High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2012; 72(5):736-40. DOI: 10.1136/annrheumdis-2012-201706. View

Coates L, Moverley A, McParland L, Brown S, Navarro-Coy N, ODwyer J . Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015; 386(10012):2489-98. PMC: 4920221. DOI: 10.1016/S0140-6736(15)00347-5. View

van Kuijk A, Reinders-Blankert P, Smeets T, Dijkmans B, Tak P . Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006; 65(12):1551-7. PMC: 1798447. DOI: 10.1136/ard.2005.050963. View

Mease P, Gottlieb A, Berman A, Drescher E, Xing J, Wong R . The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(9):2163-73. DOI: 10.1002/art.39700. View

10.

Partsch G, Steiner G, Leeb B, Dunky A, Broll H, Smolen J . Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997; 24(3):518-23. View